SanBio Obtains Partial Change Approval for“AKUUGO🄬 Suspension for Intracranial Implantation”
Appointment of Two Corporate Officers in the Quality Compliance & Regulatory Affairs Division and the Production Division
Notice Regarding Revision of Expected Approval Timing for Partial Changes to AKUUGO(R)Suspension for Intracranial Implantation
Notice of Completion of Application for Partial Change Approval of AKUUGO🄬 Suspension for Intracranial Implantation
Keita Mori, Representative Director and President of SanBio, Appointed Chairman of Samurai Biotech Association
The Results of the Third Commercial Production Run to Meet the Approval Conditions for the Shipment of AKUUGO🄬 Suspension for Intracranial Implantation
The Yield Results of the Third Commercial Production Run for AKUUGO🄬 Suspension for Intracranial Implantation
Publication of Results of Cell Implantation Location Analysis from Phase 2 Clinical Trial of Vandefitemcel (SB623) in TBI Patients (STEMTRA Trial) in Neurotrauma Reports
The Results of the Second Commercial Production Run to Meet the Approval Conditions for the Shipment of AKUUGO🄬 Suspension for Intracranial Implantation
Publication of an Article in Molecular Therapy Demonstrates That SB623 ImprovesCortical Excitability in Rats with Focal Cerebral Ischemia
